secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001641172-25-026403
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

U.S. Medicine Magazine features CyPath Lung, citing potential $895M savings and 92% sensitivity
--------------------------------------------------------------------------------

- CyPath Lung featured in U.S. Medicine pulmonary issue, highlighting improved lung cancer detection for veterans.
- Economic modeling shows up to $895M savings for private payers, $379M for Medicare if used in 2022 standard of care.
- Clinical performance: 92% sensitivity, 87% specificity, 88% accuracy in nodules ≤20 mm.
- Case studies report Stage 1A detection when PET/CT, serum markers, and risk models failed.
- Study authored by BAMC and VA pulmonologists, supporting integration into VA standard of care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000164117225026403/0001641172-25-026403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000164117225026403/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-026403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer